Cerebral perfusion as a diagnostic marker of early alzheimer’s disease

I. Prohovnik, R. Mayeux, H. A. Sackeim, G. Smith, Y. Stern, P. O. Alderson

Research output: Contribution to journalArticlepeer-review


Clinical diagnosis of Alzheimer’s disease (AD) is not fully satisfactory, and laboratory markers of this disease are not yet established. We report substantial regional Cerebral Blood Flow (rCBF) abnormalities in patients with documented early stages of the disease, when differential diagnosis is most critical. Thirty-six patients with carefully documented clinical diagnosis of early AD (mean disease duration, 3.25 ± 1.80 years) and 12 elderly healthy controls participated in rCBF studies using the 133Xe inhalation method. Whole-brain perfusion was significantly (p < 0.001) lower in the AD group, and a characteristic perfusion deficit was consistently found in temporoparietal cortex of the AD patients. Discriminant analyses demonstrated over 90% correct classification of the two groups. Two subgroups of patienta with mildest disease manifestations were equally well discriminated. The similarity of these findings to those in late stages, which have been validated neuro-pathologically, offers indirect confirmation of validity and specificity. These results suggest that rCBF procedures may provide an accurate and sensitive laboratory marker for early AD.

Original languageEnglish (US)
Pages (from-to)931-937
Number of pages7
Issue number6
StatePublished - Jun 1988
Externally publishedYes

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Cerebral perfusion as a diagnostic marker of early alzheimer’s disease'. Together they form a unique fingerprint.

Cite this